Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, H. Jean Khoury, MD, Patricia Kropf, MD, Mauricette Michallet, MD, PhD, Michele Baccarani, MD, Delphine Rea, MD, PhD, Charles Chuah, MD, Raghunadharao Digumarti, MD, Purvish M. Parikh, MD, PhD, Elizabeth Li, MS, Mihaela C. Munteanu, MS, Peter D. Brown, DPhil, Franck E. Nicolini, MD, PhD

Blood (2013) 122 (21): 2743.

https://doi.org/10.1182/blood.V122.21.2743.2743

Published: 2013

Journal Articles

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Jorge Cortes, Jeff H. Lipton, Delphine Rea, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda, Annie-Claude Benichou, Adam R. Craig, Mauricette Michallet, Franck E. Nicolini, Hagop Kantarjian

Blood (2012) 120 (13): 2573–2580.

https://doi.org/10.1182/blood-2012-03-415307

Published: 2012

Includes: Supplemental data

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Ruth Pettengell, MD, Bertrand Coiffier, MD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Pier Luigi Zinzani, MD, Gary J Schiller, MD, David A Rizzieri, MD, Paul Cernohous, Lixia Wang, Jack W. Singer, MD

Blood (2009) 114 (22): 1677.

https://doi.org/10.1182/blood.V114.22.1677.1677

Published: 2009

Journal Articles

Kinase Domain Mutations and Responses to Dose Escalation in Chronic Myeloid Leukemia Resistant to Standard Dose Imatinib Mesylate.

Senthil Rajappa, MD, Krishna Mohan Mallavarapu, Sadashivudu Gundeti, MD, Raghunadharao Digumarti, MD

Blood (2009) 114 (22): 2203.

https://doi.org/10.1182/blood.V114.22.2203.2203

Published: 2009

NARROW

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Kinase Domain Mutations and Responses to Dose Escalation in Chronic Myeloid Leukemia Resistant to Standard Dose Imatinib Mesylate.

Email alerts

ASH Publications

American Society of Hematology

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Kinase Domain Mutations and Responses to Dose Escalation in Chronic Myeloid Leukemia Resistant to Standard Dose Imatinib Mesylate.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only